PharmaShots | Incisive News in 3 Shots

Subscribe Now

Synagis & MEDI8897

AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

November 13, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us